Lupin has entered an exclusive licensing, supply, and distribution agreement with China-based Gan Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist. This drug is intended for treating type 2 diabetes and aiding weight management in overweight or obese individuals in India. Clinical data suggests Bofanglutide offers comparable or better weight loss than existing GLP-1 alternatives with the convenience of once-every-two-weeks dosing. The deal strengthens Lupin's diabetes portfolio and expands its presence in the obesity segment, addressing a significant health concern in India.